美股A股
StockGist
Back
8-K2026-07-31· merged:deepseek-v4-flash

BTSG · BrightSpring Health Services, Inc. Common Stock

0001193125-26-326654

SEC filing

Summary

BrightSpring二季度营收利润大增,上调全年指引,核心驱动为Pharmacy Solutions强劲增长。

Key takeaways

Full analysis

指标本期去年同期同比
Revenue$3,873M$3,148M+23.0%
Gross Profit$493M$375M+31.5%
Operating Income$130.4M$48.6M—
Net Income$87M$9M—
Diluted EPS (Continuing Operations, GAAP)$0.39$0.04—
Adjusted EBITDA (Non-GAAP)$206M$143M+44.2%
Adjusted EPS (Non-GAAP)$0.45$0.22—
Pharmacy Solutions Revenue$3,407M$2,790M+22%
Provider Services Revenue$466M$358M+30%
Pharmacy Solutions Segment EBITDA$180M$125M+44%
Provider Services Segment EBITDA$75M$56M+33%
Leverage2.15x——
期间指标指引口径
FY2026Revenue$15,100M - $15,425M持续经营
FY2026Pharmacy Segment Revenue$13,200M - $13,500M持续经营
FY2026Provider Segment Revenue$1,900M - $1,925M持续经营
FY2026Adjusted EBITDA$820M - $845MNon-GAAP

简评

BrightSpring 二季度业绩表现强劲,营收同比增长 23.0% 至 $3,873M,主要受 Pharmacy Solutions 业务驱动(营收 +22%),其中每处方收入同比提升 22% 至 $314.20,抵消了处方量的小幅下滑(-0%)。Provider Services 营收增长 30%,Home Health Care 日均人数大增 54% 至 46,448,显示业务扩张动能充足。盈利能力显著改善,Adjusted EBITDA 同比增长 44.2% 至 $206M,毛利率从 11.9% 提升至 12.7%,反映业务组合优化和运营杠杆效应。净收入从 $9M 大幅增至 $87M,主要受益于营收增长和利息费用下降。

管理层上调全年指引,营收预期从 $15,100M 至 $15,425M(+17.0%-19.5%),Adjusted EBITDA 预期 $820M 至 $845M(+32.8%-36.8%),体现对下半年业务持续增长的信心。公司完成 Community Living 业务剥离,聚焦核心业务,同时通过 $300M 债务偿还和利率再融资降低杠杆至 2.15x,并完成 $60M 股票回购。CEO Jon Rousseau 强调"质量聚焦、服务表现和对患者的承诺",认为各业务线具有长期增长机会。主要风险包括 Medicare/Medicaid 费率变化、药品定价与 PBM 合同变动,以及并购整合执行风险。